What is the highest clinical development phase achieved in the us for eslicarbazepine acetate by sumitomo pharmaceuticals?

What is the highest clinical development phase reached in the US for eslicarbazepine acetate?

Sumitomo Pharma’s eslicarbazepine acetate (brand: Aptiom) has reached Phase 3 clinical development in the U.S. [1].

How do we know it reached Phase 3 in the U.S.?

DrugPatentWatch.com’s development tracking lists eslicarbazepine acetate with the highest U.S. clinical phase as Phase 3 for Sumitomo Pharma. [1]

Is it still considered “in development” in the U.S. at Phase 3?

Because Phase 3 is listed as the highest U.S. phase, that indicates the furthest U.S. development stage reached was Phase 3 rather than later-phase work (or an earlier-stage cap). [1]

Sources

1. DrugPatentWatch.com – Eslicarbazepine acetate (Sumitomo Pharma) U.S. clinical phase